Holen Sie sich die Stockscreener-App
33.84
0.30%
0.10
Handel nachbörslich:
33.63
-0.21
-0.62%
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Expands Team with 101,974 Shares in RSU Grants to 36 New Biotech Talents - Stock Titan
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - Yahoo
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance
Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com
Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - Yahoo Finance
BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus
BridgeBio launches landmark ATTR prevention study - Investing.com Australia
BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - Yahoo Finance
BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus
BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times
(BBIO) Trading Report - news.stocktradersdaily.com
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times
Recursion cuts nearly half of its pipeline - statnews.com
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch - The Globe and Mail
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales - insights.citeline.com
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio sales of new heart drug outstrip expectations - BioPharma Dive
BridgeBio (BBIO) Price Target Increased by Scotiabank Analyst | - GuruFocus
Attruby's Momentum and an Advancing Pipeline Support BridgeBio's Long-Term Growth Outlook - Morningstar
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Perf - GuruFocus
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Performance | BBIO Stock News - GuruFocus
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating - marketscreener.com
BridgeBio (BBIO) Price Target Uplifted by BofA Analyst Amid Stro - GuruFocus
Scotiabank raises BridgeBio stock target to $55 on strong sales By Investing.com - Investing.com India
Scotiabank raises BridgeBio stock target to $55 on strong sales - Investing.com
BridgeBio price target raised to $63 from $46 at Piper Sandler - TipRanks
BridgeBio (BBIO) Target Price Increased by Piper Sandler Followi - GuruFocus
BridgeBio (BBIO) Target Price Increased by Piper Sandler Following Strong Quarter | BBIO Stock News - GuruFocus
BridgeBio’s Attruby outperforms sales expectations, shares rise - Endpoints News
BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50 - TipRanks
(BBIO) Trading Advice - news.stocktradersdaily.com
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma: Q1 Earnings Snapshot - CT Insider
BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress - TipRanks
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth By Investing.com - Investing.com Nigeria
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth - Investing.com
BridgeBio Pharma, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (BBIO) Reports Strong Q1 Earnings, Shares Rise - GuruFocus
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):